The stock has a 36-month beta value of 0.72. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMTX is 71.66M, and at present, short sellers hold a 12.41% of that float. On May 10, 2024, the average trading volume of IMTX was 419.17K shares.
IMTX) stock’s latest price update
Immatics N.V (NASDAQ: IMTX)’s stock price has plunge by 2.63relation to previous closing price of 10.64. Nevertheless, the company has seen a 1.39% surge in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-27 that Immatics, a German biotech company, achieved its Nasdaq listing in 2020 through a merger with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advisors. The company focuses on developing T-cell receptor-based immunotherapies for solid tumors with unmet medical needs. Immatics has partnerships with Bristol Myers Squibb, Moderna, and Editas, and is advancing multiple candidates in clinical studies.
IMTX’s Market Performance
Immatics N.V (IMTX) has seen a 1.39% rise in stock performance for the week, with a 0.74% gain in the past month and a -4.13% plunge in the past quarter. The volatility ratio for the week is 2.54%, and the volatility levels for the past 30 days are at 4.00% for IMTX. The simple moving average for the past 20 days is 5.13% for IMTX’s stock, with a 1.06% simple moving average for the past 200 days.
Analysts’ Opinion of IMTX
Mizuho, on the other hand, stated in their research note that they expect to see IMTX reach a price target of $12. The rating they have provided for IMTX stocks is “Buy” according to the report published on March 31st, 2023.
Bryan Garnier gave a rating of “Buy” to IMTX, setting the target price at $16 in the report published on March 24th of the previous year.
IMTX Trading at -1.51% from the 50-Day Moving Average
After a stumble in the market that brought IMTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.02% of loss for the given period.
Volatility was left at 4.00%, however, over the last 30 days, the volatility rate increased by 2.54%, as shares surge +3.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.40% lower at present.
During the last 5 trading sessions, IMTX rose by +1.75%, which changed the moving average for the period of 200-days by -7.98% in comparison to the 20-day moving average, which settled at $10.40. In addition, Immatics N.V saw 3.70% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IMTX
Current profitability levels for the company are sitting at:
- -1.88 for the present operating margin
- -1.2 for the gross margin
The net margin for Immatics N.V stands at -1.71. The total capital return value is set at -0.29.
Based on Immatics N.V (IMTX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -122.56.
Currently, EBITDA for the company is -80.65 million with net debt to EBITDA at 2.52. When we switch over and look at the enterprise to sales, we see a ratio of 15.46. The receivables turnover for the company is 9.41for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.87.
Conclusion
To sum up, Immatics N.V (IMTX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
